Environmental Health Department, Boston University School of Public Health, 715 Albany Street, Boston, Massachusetts 02118, United States.
Division of Intramural Research, Biostatistics and Computational Biology Branch, and National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods, National Institute of Environmental Health Sciences, 111 T.W. Alexander Drive, Durham, North Carolina 27709, United States.
Environ Sci Technol. 2022 May 3;56(9):5620-5631. doi: 10.1021/acs.est.1c07143. Epub 2022 Apr 21.
Chemical-induced alteration of maternal thyroid hormone levels may increase the risk of adverse neurodevelopmental outcomes in offspring. US federal risk assessments rely almost exclusively on apical endpoints in animal models for deriving points of departure (PODs). New approach methodologies (NAMs) such as high-throughput screening (HTS) and mechanistically informative in vitro human cell-based systems, combined with in vitro to in vivo extrapolation (IVIVE), supplement in vivo studies and provide an alternative approach to calculate/determine PODs. We examine how parameterization of IVIVE models impacts the comparison between IVIVE-derived equivalent administered doses (EADs) from thyroid-relevant in vitro assays and the POD values that serve as the basis for risk assessments. Pesticide chemicals with thyroid-based in vitro bioactivity data from the US Tox21 HTS program were included ( = 45). Depending on the model structure used for IVIVE analysis, up to 35 chemicals produced EAD values lower than the POD. A total of 10 chemicals produced EAD values higher than the POD regardless of the model structure. The relationship between IVIVE-derived EAD values and the in vivo-derived POD values is highly dependent on model parameterization. Here, we derive a range of potentially thyroid-relevant doses that incorporate uncertainty in modeling choices and in vitro assay data.
化学物质诱导的母体甲状腺激素水平改变可能会增加后代不良神经发育结果的风险。美国联邦风险评估几乎完全依赖于动物模型中的顶端终点来推导出起始点 (POD)。新方法学 (NAMs),如高通量筛选 (HTS) 和基于机制的体外人类细胞系统,与体外到体内外推 (IVIVE) 相结合,补充了体内研究,并提供了一种替代方法来计算/确定 POD。我们研究了 IVIVE 模型的参数化如何影响甲状腺相关体外测定中源自 IVIVE 的等效给药剂量 (EAD) 与作为风险评估基础的 POD 值之间的比较。纳入了来自美国 Tox21 HTS 计划的具有甲状腺体外生物活性数据的农药化学品(n=45)。根据用于 IVIVE 分析的模型结构,多达 35 种化学品的 EAD 值低于 POD。共有 10 种化学品的 EAD 值高于 POD,无论模型结构如何。IVIVE 衍生的 EAD 值与体内衍生的 POD 值之间的关系高度依赖于模型参数化。在这里,我们推导出了一系列可能与甲状腺相关的剂量,其中包括建模选择和体外测定数据的不确定性。